Three-Year Follow-up on Safety and Effectiveness of Rituximab Plus Chemotherapy As First-Line Treatment of Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Feng, Jifeng
Wu, Jianqiu
Song, Yongping
Su, Liping
Zhang, Mingzhi
Li, Wei
Hu, Yu
Zhang, Xiaohong
Gao, Yuhuan
Niu, Zuoxing
Feng, Ru
Wang, Wei
Peng, Jiewen
Li, Xiaolin
Ouyang, Xuenong
Wu, Changping
Zhang, Weijing
Zeng, Yun
Xiao, Zhen
Liang, Yingmin
Zhuang, Yongzhi
Wang, Jishi
Sun, Zimin
Bai, Hai
Cui, Tongjian
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5208
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Mechanism and Treatment of Rituximab Resistance in Diffuse Large B-cell Lymphoma
    Zou, Linqing
    Song, Guoqi
    Gu, Siyu
    Kong, Lingling
    Sun, Shiqi
    Yang, Li
    Cho, William C.
    CURRENT CANCER DRUG TARGETS, 2019, 19 (09) : 681 - 687
  • [32] Rituximab in the treatment of diffuse large B-cell lymphoma primary of the lung
    Aviles, Agustin
    Nambo, Maria J.
    Huerta-Guzman, Judith
    Silva, Luis
    Neri, Natividad
    HEMATOLOGY, 2013, 18 (02) : 81 - 84
  • [33] Rituximab in treatment of primary gastric diffuse large B-cell lymphoma
    Zhang, Jian
    Li, Gang
    Yang, Haiyan
    Liu, Xiaojian
    Cao, Junning
    LEUKEMIA & LYMPHOMA, 2012, 53 (11) : 2175 - 2181
  • [34] The effect of an ambulatory medical assistance during chemotherapy and follow-up among patient with diffuse large B-cell lymphoma on treatment adherence
    Lamy, Sebastien
    Rueter, Manuela
    Jeanneau, Pauline
    Nogaro, Jean-claude
    Lapeyre-Mestre, Maryse
    Borel, Cecile
    Campacl, Gisele
    Delplerre, Cyrille
    Despas, Fabien
    Laurent, Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Evaluation of fetal cell transplantation safety in treatment of diabetes: A three-year follow-up
    Nasli-Esfahani E.
    Ghodsi M.
    Amini P.
    Keshtkar A.A.
    Amiri S.
    Mojahed-Yazdi N.
    Tootee A.
    Larijani B.
    Journal of Diabetes & Metabolic Disorders, 14 (1):
  • [36] Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP
    Kobayashi, Yujin
    Hatta, Yoshihiro
    Hojo, Atsuko
    Kura, Yoshimasa
    Uchino, Yoshihito
    Takahashi, Hiromichi
    Kiso, Satomi
    Hirabayashi, Yukio
    Yagi, Mai
    Kodaira, Hitomi
    Kurita, Daisuke
    Tanaka, Toshitake
    Miura, Katsuhiro
    Iriyama, Noriyoshi
    Kobayashi, Sumiko
    Sawada, Umihiko
    Sugitani, Masahiko
    Takeuchi, Jin
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 3 (02) : 304 - 308
  • [37] Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy
    Petrausch, U.
    Samaras, P.
    Haile, S. R.
    Veit-Haibach, P.
    Soyka, J. D.
    Knuth, A.
    Hany, T. F.
    Mischo, A.
    Renner, C.
    Schaefer, N. G.
    ANNALS OF ONCOLOGY, 2010, 21 (08) : 1694 - 1698
  • [38] EECC FOR EVALUATING THE SAFETY OF SUBCUTANEOUS RITUXIMAB IN THE FIRST LINE TREATMENT OF DIFFUSE LARGE CELL B LYMPHOMA OR FOLLICULAR NON HODGKIN LYMPHOMA
    Munoz Ricardo, Garcia
    Blanco Cristina, Quero
    Persona Ernesto, Perez
    Garcia Abel, Domingo
    Lopez Cristina, Perez
    Maria Teresa, Villaescusa de la Rosa
    Ana Margarita, Martinez Castro
    Calvillo Mercedes, Rodriguez
    Tauler Rocio, Sanchez
    Santos Carlos, Panizo
    HAEMATOLOGICA, 2016, 101 : 222 - 223
  • [39] Secondary Malignancies in Diffuse Large B-cell Lymphoma Survivors With 40 Years of Follow-Up: Influence of Chemotherapy and Radiotherapy
    Rock, C. B.
    Parsons, M. W.
    Chipman, J.
    Shah, H.
    Hu, B.
    Stevens, D. M.
    Tao, R.
    Tward, J. D.
    Gaffney, D. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : S81 - S82
  • [40] Primary cutaneous B-cell lymphoma mimicking pyoderma gangrenosum: first-line treatment with rituximab
    Lami, MC
    Vabres, P
    Dreyfus, B
    Germain, T
    Guillet, G
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 (01) : 250 - 252
12345